Menu

Filtros : "NEOPLASIAS" "Hungria" Removido: "FE-EDM" Limpar

Filtros

Refine with date range

  • 1

1 - 2 (2 records)

  • Artigo de periodico

    Assessing the chemical composition, potential toxicity and cancer risk of airborne fine particulate matter (PM2.5) near a petrochemical industrial area (2023)

    Caumo, Sofia ; Yera, Aleinnys B; Alves, Célia ; Rienda, Ismael Casotti; Kovats, Nora; Hubai, Katalin; Vasconcellos, Pérola de Castro

    Source: Environmental Toxicology and Pharmacology. Unidade: IQ

    Subjects: NEOPLASIAS, FARMACOLOGIA

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      CAUMO, Sofia et al. Assessing the chemical composition, potential toxicity and cancer risk of airborne fine particulate matter (PM2.5) near a petrochemical industrial area. Environmental Toxicology and Pharmacology, v. 101, p. 1-11 art. 104170, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.etap.2023.104170. Acesso em: 14 jun. 2024.

    • APA

      Caumo, S., Yera, A. B., Alves, C., Rienda, I. C., Kovats, N., Hubai, K., & Vasconcellos, P. de C. (2023). Assessing the chemical composition, potential toxicity and cancer risk of airborne fine particulate matter (PM2.5) near a petrochemical industrial area. Environmental Toxicology and Pharmacology, 101, 1-11 art. 104170. doi:10.1016/j.etap.2023.104170

    • NLM

      Caumo S, Yera AB, Alves C, Rienda IC, Kovats N, Hubai K, Vasconcellos P de C. Assessing the chemical composition, potential toxicity and cancer risk of airborne fine particulate matter (PM2.5) near a petrochemical industrial area [Internet]. Environmental Toxicology and Pharmacology. 2023 ; 101 1-11 art. 104170.[citado 2024 jun. 14 ] Available from: https://doi.org/10.1016/j.etap.2023.104170

    • Vancouver

      Caumo S, Yera AB, Alves C, Rienda IC, Kovats N, Hubai K, Vasconcellos P de C. Assessing the chemical composition, potential toxicity and cancer risk of airborne fine particulate matter (PM2.5) near a petrochemical industrial area [Internet]. Environmental Toxicology and Pharmacology. 2023 ; 101 1-11 art. 104170.[citado 2024 jun. 14 ] Available from: https://doi.org/10.1016/j.etap.2023.104170

  • Artigo de periodico

    Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk (2015)

    Spina, M.; Nagy, Z.; Ribera, J. M.; Federico, M.; Aurer, I.; Jordan, K.; Borsaru, G.; Pristupa, A. S.; Bosi, A.; Grosicki, S.; Glushko, N. L.; Ristic, D.; Jakucs, J.; Montesinos, P.; Mayer, J.; Rego, Eduardo Magalhães; Baldini, S.; Scartoni, S.; Capriati, A.; Maggi, C. A.; Simonelli, C.

    Source: Annals of Oncology. Unidade: FMRP

    Subjects: NEOPLASIAS, HEMATOLOGIA, RIM, ÁCIDO ÚRICO, DOENÇAS HEMATOLÓGICAS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SPINA, M. et al. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, v. 26, n. 10, p. 2155-2161, 2015Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdv317. Acesso em: 14 jun. 2024.

    • APA

      Spina, M., Nagy, Z., Ribera, J. M., Federico, M., Aurer, I., Jordan, K., et al. (2015). Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 26( 10), 2155-2161. doi:10.1093/annonc/mdv317

    • NLM

      Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2024 jun. 14 ] Available from: https://doi.org/10.1093/annonc/mdv317

    • Vancouver

      Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2024 jun. 14 ] Available from: https://doi.org/10.1093/annonc/mdv317
  • 1

1 - 2 (2 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024